Page 1 of 18

Current sampling and sequencing biases of Lassa mammarenavirus limit inference from phylogeography and molecular epidemiology in Lassa Fever endemic regions.

3 4

1

2

5 Authors

- 6 Liã Bárbara Arruda^{1b#}, Hayley Beth Free^{2a§}, David Simons^{2§}, Rashid Ansumana³, Linzy Elton¹,
- 7 Najmul Haider^{2c}, Isobella Honeyborne¹, Danny Asogun⁴, Timothy D McHugh¹, Francine
- 8 Ntoumi^{5,6}, Alimuddin Zumla^{1,7}, Richard Kock²
- 9

10 Affiliations

- ¹ Centre for Clinical Microbiology, Division of Infection and Immunity, University College
- 12 London, London, UK
- ² The Royal Veterinary College, University of London, Hatfield, UK.
- ³ School of Community Health Sciences, Njala University, Bo, Sierra Leone
- ⁴ Ekpoma and Irrua Specialist Teaching Hospital, Ambrose Alli University, Irrua, Nigeria.
- ⁵ Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville, Republic of Congo
- ⁶ Institute for Tropical Medicine, University of Tübingen, Germany
- 18 ⁷ NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK
- ¹⁹ ^a Current affiliation Oxford Brookes University, Oxford, UK
- 20 ^b Current affiliation Wellcome Connecting Science, Hinxton, UK
- ^c Current affiliation School of Life Sciences, Faculty of Natural Sciences, Keele University,
- 22 Staffordshire, United Kingdom
- 23 § Both authors contributed equality to this work
- 24 # Corresponding author
- 25
- 26

Page 2 of 18

27 Abstract

Lassa fever (LF) is a potentially lethal viral haemorrhagic infection of humans caused by Lassa 28 29 mammarenavirus (LASV). It is an important endemic zoonotic disease in West Africa with growing evidence for increasing frequency and sizes of outbreaks. Phylogeographic and 30 31 molecular epidemiology methods have projected expansion of the Lassa fever endemic zone 32 in the context of future global change. The Natal multimammate mouse (Mastomys natalensis) 33 is the predominant LASV reservoir, with few studies investigating the role of other animal 34 species. To explore host sequencing biases, all LASV nucleotide sequences and associated 35 metadata available on GenBank (n = 2,298) were retrieved. Most data originated from Nigeria (54%), Guinea (20%) and Sierra Leone (14%). Data from non-human hosts (n = 703) were 36 limited and only 69 sequences encompassed complete genes. We found a strong positive 37 correlation between the number of confirmed human cases and sequences at the country level 38 (r = 0.93 (95% Confidence Interval = 0.71 - 0.98), p < 0.001) but no correlation exists between 39 confirmed cases and the number of available rodent sequences (r = -0.019 (95% C.I. -0.71 -40 0.69), p = 0.96). Spatial modelling of sequencing effort highlighted current biases in locations 41 42 of available sequences, with increased effort observed in Southern Guinea and Southern Nigeria. Phylogenetic analyses showed geographic clustering of LASV lineages, suggestive 43 of isolated events of human-to-rodent transmission and the emergence of currently circulating 44 strains of LASV from the year 1498 in Nigeria. Overall, the current study highlights significant 45 geographic limitations in LASV surveillance, particularly, in non-human hosts. Further 46 47 investigation of the non-human reservoir of LASV, alongside expanded surveillance, are 48 required for precise characterisation of the emergence and dispersal of LASV. Accurate 49 surveillance of LASV circulation in non-human hosts is vital to guide early detection and initiation of public health interventions for future Lassa fever outbreaks. 50

51

52 Key-words

53 Lassa mammarenavirus; Lassa Fever; Phylogeography; Metadata; Zoonoses; Surveillance

- 54
- 55

Page 3 of 18

56 **1 Introduction**

57

58 Lassa fever (LF) is a lethal zoonotic viral haemorrhagic disease of humans, caused by Lassa mammarenavirus (LASV). It causes an estimated 900,000 annual human infections and 59 60 several thousand deaths in West Africa annually (1,2). The WHO assigns LASV endemicity to eight West African countries: Benin, Ghana, Guinea, Liberia, Mali, Sierra Leone, Togo and 61 Nigeria (S1 Fig) (3). LASV is a bisegmented ssRNA- virus of the family Arenaviridae (4.5). 62 Based on the genomic analysis of the large (L) and small segments (S) LASV has been 63 classified into seven lineages which demonstrate spatial segregation across the endemic 64 range (6). The high nucleotide variability (25-32%) of these lineages introduces complexity 65 into assays to detect LASV infection. 66

67

Epidemiological data on LF is limited and constrained by current testing and reporting in the 68 endemic region, making accurate estimates of its true burden challenging (7). Many individuals 69 infected with LASV do not seek healthcare with up to 80% of infections assumed 70 71 asymptomatic or presenting as mild illness (8). Estimates based on longitudinal serological 72 surveys in Sierra Leone in the early 1980's indicated that 100,000 to 300,000 infections of LF 73 occurred annually in West Africa, with more recent estimates being up to 900,000 infections 74 (2,8). Identification of symptomatic cases is further confounded by overlapping symptoms with 75 other diseases (e.g., malaria) and lack of available diagnostic methods (1,9-11). Access to diagnostic tests varies spatially, increased availability at centers of excellence in LF treatment 76 and research such as the Irrua Specialist Teaching Hospital, Nigeria and Kenema General 77 Hospital, Sierra Leone results in a spatial bias of reported cases from these locations. 78 79 Phylogenetic analysis and molecular dating of sequence clinical and research samples suggest a westward route of dispersal of LASV lineages, from the most recent common 80 ancestor in Nigeria. (12-18). These estimates have been used to project the potential for 81 82 Lassa Fever to extend beyond the current endemic zone (19).

83

The Natal multimammate mouse (Mastomys natalensis) is the primary reservoir of LASV. 84 85 however, 11 other rodent species have been found to be acutely infected or have seropositivity 86 to LASV including; Mastomys erythroleucus, Hylomyscus pamfi, Mus baoulei and Rattus rattus (15,20-24). Humans become infected with LASV upon contact with or inhalation of 87 88 excretions from the rodent species (12,25). Although human-to-human transmission has been 89 reported – typically associated with nosocomial outbreaks – these are rare events when compared with spillover from rodent hosts (26). We performed a study of LASV nucleotide 90 sequences available from the National Centre for Biotechnology Information (NCBI) GenBank, 91 92 using associated metadata to spatially model sequencing effort, adjusted for the number of

Page 4 of 18

suspected and confirmed human LF cases to determine potential biases in locations of
 available sequences or significant geographic limitations in LASV surveillance, particularly, in
 non-human hosts.

96 97

2 Methods

98 99

100 2.1 Data Collection and Processing

101

LASV nucleotide and protein sequences were obtained from the NCBI GenBank (27). The 102 search query run on 24 Sep 2021 was for "Lassa mammarenavirus" in the organism field of 103 the NCBI nucleotide dataset. Data were obtained using the NCBI Entrez API with analysis 104 conducted using the "genbankr" package within the R statistical programming language (27-105 29). Associated citations were manually retrieved to identify missing metadata for sequences 106 including hosts and geographic location of samples. Sequences with large portions (10% 107 missing compared to reference sequences, NC 004296.1 and NC 004297.1 for S and L 108 109 segments respectively) of missing nucleotide data on the L- or S-segment or lacking 110 associated metadata (collection year, host species, country, and geographical region of sampling) were excluded from phylogenetic analysis. Nucleotide sequences were aligned 111 using the 'map to reference' tool on Geneious Prime 20201.2. Alignment, visual inspection 112 and manual editing were performed, and entries that contained >100 continuous ambiguous 113 114 nucleotide calls were excluded (S1 Data).

115

116 **2.2 Sequencing Bias**

117

First, we compared the number of cases reported from countries between 2008-2023 with the number of samples contained in GenBank to summarise the correlation between reported human cases and availability of sequences. We then compared the proportion of human to non-human derived sequences within countries.

122

To understand the bias of sequenced samples at a sub-national level the origin of a sequenced sample was geocoded using the Google Geocoding API using the "ggmap" package (30). Sequence locations were associated with level-1 administrative regions and data were separated into human and rodent sources of samples to visualise the spatial heterogeneity of sampling. To measure sampling effort bias, the number of samples obtained within a level-1 administrative region was associated with the centroid of the region. The number of confirmed LF clinical cases reported from these regions in the previous 15 years was obtained (S2 Data).

Page 5 of 18

The number of cases within a region was divided by the human population count to produce the number of confirmed cases per 100,000 individuals. The number of sequences was used as the response variable in a spatial Generalised Additive Model, with geographic coordinates and cases per 100,000 individuals used as covariates. This model was constructed using the "mgcv" package (31).

135

136 2.3 Phylogenetic Analysis

137

Phylogenetic analysis was undertaken through Bayesian Markov Chain Monte Carlo (MCMC) 138 method using BEAST.v1.10.4 (32). In BEAUTi, the parameters were a substitution model as 139 a generalised time reversible plus gamma site heterogeneity, with codon partition positions 1, 140 2, 3. A strict clock and a coalescent tree prior with a constant size population was used. Each 141 analysis consisted of 20 million MCMC steps and trees were sampled every 20,000 142 generations. Sample collection dates from the metadata were used as tip dates to fit to a 143 molecular clock, and country of sample collection was incorporated as a discrete state (16,33). 144 145 To assess the log files of the output TRACER.v.1.7.1 was used. Maximum-clade credibility 146 trees were generated through TreeAnnotator v1.8.4 and visualised in FigTree.v1.4.4 (34).

- 147
- 148 **3**
- 149

150

3.1 Compiled Dataset

Results

151

The initial dataset comprised 2,298 records (from samples obtained 1969-2019), including nucleotide sequences and associated metadata. Incomplete gene sequences and sequences lacking metadata information (n = 1,045) were removed from phylogenetic analyses. Therefore, 680 sequences of complete S segment and 573 sequences of partial L segment (L protein only) were used. Accession numbers of included and excluded sequences are available in S1 Data.

158

159 3.2 Descriptive Analysis

160

Year of collection was available for 2,108 records, with the oldest sequence dating from 1969 and latest from 2019. Among these records, most sequences (n = 1,936, 92%) have been obtained since 2008. Human-derived LASV sequences comprised most of the available records (67%), other host species include *Mastomys natalensis* (29%) and *Mastomys spp.* (3%), while *Mastomys erythroleucus* (n = 18), *Mus baoulei* (n = 9) and *Hylomyscus pamfi* (n = 10) represent < 1% each. The species sampled was not documented in 107 records. Country

Page 6 of 18

of collection was available for 2,238 records. Most sequences were produced from samples collected in Nigeria (54%), followed by Guinea (20%), Sierra Leone (14%), Liberia (4%) and Cote d'Ivoire (3%) with the remainder obtained from, Benin, Ghana, Mali and Togo (Fig 1).

170

171 Sequences for human derived samples with regional location data (n = 1328, 63%) were

172 clustered in Edo State, Nigeria (n = 519, 39%), Ondo State, Nigeria (n = 220, 17%) and

173 Eastern Province, Sierra Leone (n = 159, 12%) with 430 samples from the remaining endemic

regions. Sequences from rodent samples with regional location data (n = 527, 25%) were most

175 commonly obtained from Faranah, Guinea (n = 210, 39%) and Eastern Province, Sierra Leone

- (n = 107, 20%) with 210 samples from the regions.
- 177



Page 8 of 18

Figure 1 – The number of sequences, shown on a log_{10} scale, retrieved from NCBI GenBank with associated regional sampling location and host for human samples (top, n = 1,328) and rodent samples (bottom, n = 527). Grey regions represent level-1 administrative areas with no sequences within countries that have at least one available sequence. White countries are West African countries with no available LASV sequences. See S1 Fig for country names. Shapefiles for basemap layer obtained from GADM 4.0.2 (35)

- 185
- 186

187 3.3 Sequencing bias

188

We observed a strong positive correlation between the number of confirmed human cases between 2008-2023 and the number of GenBank deposited sequences at country level (r(degrees of freedom = 7) = 0.93 (95% Confidence Interval = 0.71-0.98), p < 0.001). When analysed by species source no correlation was observed with the number of confirmed cases and the number of available rodent sequences was observed (r(6) = -0.019 (95% C.I. -0.71-0.69), p = 0.96).

195

When combining both human and rodent-derived samples at the regional level to explore spatial sampling biases, we found that sequencing effort is greatest in Southwest Nigeria, centred over Edo State and the Faranah and Nzérékoré regions of Guinea, Eastern Province of Sierra Leone and Nimba district of Liberia (Fig 2). There was a positive, non-linear association between the rate of confirmed human cases with the number of available rodent and human derived LASV sequences at regional level (deviance explained = 14%, estimated degrees of freedom = 2.29, p < 0.001).

Page 9 of 18



204

Figure 2 – Modelled relative sequencing effort derived from both human and rodent samples.
Greatest sequencing effort coincides with areas where sampling in humans (Edo, Nigeria and
Kenema, Sierra Leone) and rodents (Faranah, Guinea) have historically been focussed.
Shapefiles for basemap layer obtained from GADM 4.0.2 (35)

209

210

3.4 Phylogenetic Analysis

(Table 1).

Sequences for each segment of LASV showed clustering according to previously documented
lineages I-VII alongside geographical clustering with lineages I-III and VI present in Nigeria,
IV in Liberia, Guinea and Sierra Leone, V in Mali and VII in Togo (S2 Fig). In this analysis only
L segment sequences of lineage V from Cote d'Ivoire were included due to quality control
exclusion criteria. The phylogeny of the L segment indicates an older emergence of LASV in
the human population, with the most recent common ancestor (MRCA) predicted in the year
828 in Nigeria, inference based on the S segment indicates the emergence in the year 1350

Page 10 of 18

- Table 1 The most recent common ancestor (MRCA) stratified by host and country of
- collection of Lassa mammarenavirus (LASV) S and L segments. Samples were collected
- 223 between 1969-2018.

Host species	Country	S segment MRCA	L segment MRCA
Homo sapiens (n=1181)	Benin	1995	1989
	Guinea	1895	1871
	Liberia	1895	1627
	Nigeria	1681	1498
	Sierra Leone	1901	1874
	Тодо	2016	2014
Hylomyscus pamfi (n=2)	Nigeria	1681	1498
Mastomys erythroleucus (n=18)	Guinea	1975	2010
	Nigeria	2008	2006
Mastomys natalensis (n=36)	Guinea	1938	1997
	Mali	1951	2007
	Sierra Leone	1909	1979

224

There was a lack of sequence information from lineage I and VI, however, phylogeny suggests 225 these lineages are basal to others in Nigeria (S2 Fig). Lineage VII in Togo is most closely 226 227 related to Nigerian isolates and potentially diverged between 500-900 years ago. The 228 divergence of lineage III and IV is predicted to have occurred between the years 1332-1551. 229 Introduction to countries west of Nigeria appears to be by dispersal initially to Liberia, followed 230 by Guinea in the 1700s, followed by Sierra Leone and Mali approximately 100 years later. A lack of full segment sequences from lineage V limits calculation of divergence from the most 231 recent common ancestor from lineage IV (approximately 200 years). 232

- 233
- 234

235 4 Discussion

236

There are several important aspects of our study and findings. First, we studied a comprehensive dataset of publicly available full-segment LASV sequences, spanning West Africa and host species, to inform our understanding of the phylogeny of LASV dispersal. Second, we identified substantial variability in the origin of available sequences and completeness of records. Third, we showed strong geographic clustering among lineages supporting prior hypotheses of radiation from both Nigeria and a subsequent introduction into Liberia (19). Fourth, the synthesis of available metadata highlights important gaps in currently

Page 11 of 18

available data, including spatial bias in the sequencing of samples and suggests this shouldbe used to inform the design of epidemiological programmes going forward.

246

Our analyses of 2,298 LASV sequences obtained from GenBank highlights the spatial biases 247 248 in the availability of sequence data that may limit our understanding of the current and historic dispersal of LASV lineages in West Africa. First, sequence data was typically obtained from 249 three of the eight endemic countries: Nigeria, Guinea and Sierra Leone. We found a strong 250 251 associated between the number of reported human cases and number of available sequences. When stratifying by host species this trend did not remain with rodent derived samples 252 showing no association with the number of human cases indicating important under-sampling 253 in high human cases regions and relatively high sampling in locations with low numbers of 254 human cases. This is potentially an important source of bias when attempting to infer 255 phylogeography within the reservoir host of this zoonotic pathogen. Sequence data from other 256 countries, and more regions within them, across West Africa are required to increase 257 confidence in the timelines of the currently inferred westward expansion. Greater focus needs 258 259 to be placed on acquiring sequences from the rodent host to understand viral genetic diversity 260 within the primary reservoir species. Comparing rodent derived sequences with those 261 acquired from spillover into human populations may also allow identification of genetic drivers 262 of transmission (36).

263

The overrepresentation of data from these three countries has been mapped as relative 264 sequencing effort to identify regions where increased LASV sequencing are required to 265 counteract current sequencing biases. Second, geographic clustering of LASV lineages, 266 suggest isolated events of human-to-rodent transmission and the emergence of LASV dating 267 from 1498 in Nigeria. Similarly, Olayemi et al. report evidence of earlier emergence of the virus 268 269 in humans than in rodents in Nigeria (16). Comparatively limited data from non-human hosts with limited genome coverage, (69/703 sequences encompassed complete genes) produce 270 important uncertainty around the observation of human-to-rodent transmission. Taken 271 together, this data highlight limited surveillance among animal species, necessitating further 272 273 investments in data acquisition and sharing to accurately define the spatiotemporal expansion 274 of LASV in West Africa.

275

The phylogenetic analysis of LASV stratified by host species supports spatial evolution, in addition to intra-host viral evolution (S2 Fig). For instance, LASV sequences from *M. erytholeucus* sampled in Nigeria and Guinea clustered within lineages III and IV, respectively. Interestingly, these isolates appear to occur after the emergence of the most recent common ancestor virus circulating among humans and *M. natalensis* in these countries (Table 1),

Page 12 of 18

281 suggesting introduction of LASV into M. erythroleucus populations was a consequence of 282 pathogen circulation in human and *M. natalensis* populations. Sequences from *M. natalensis* 283 in Sierra Leone exhibit minimal clustering, and were interspersed with sequences from humans, potentially representing isolated events of pathogen introduction into human 284 285 populations with spillback into commensal rodent populations (i.e., reverse zoonosis). The most recent common ancestor of LASV sequences from *M. natalensis* in Sierra Leone suggest 286 a later emergence of the virus in this country. Our findings corroborate those of Olayemi et al., 287 288 that within Sierra Leone LASV appears to have emerged in human hosts before rodents (16). 289 However, this data must be caveated by the limited information from rodent species in these locations. 290

291

There is a lower coverage of rodent-derived LASV sequences, with those from the primary 292 293 reservoir *M. natalensis* forming fewer than one-third of all sequences (n = 642, 28%), with substantially lower sampling of other possible rodent hosts, including other Mastomys species. 294 295 Rodent sampling has not increased at the same rate as human samples despite increased 296 sampling effort since 2008 (15,22,37). There is substantial heterogeneity in the locations in 297 which rodent and human samples are available. For example, a relatively high number of 298 rodent samples (n = 429) have been obtained from Guinea while few human sequences (n = 1000299 20) are available from these locations. The inverse is true of Nigeria where most human 300 derived sequences are obtained (n = 1,147) but only 85 rodent sequences are available, and all of these from a single state (Edo, Nigeria). The number of suspected and reported cases 301 was found to be positively but non-linearly associated with the number of available sequences. 302 This is suggestive of a consolidation of research and focus of sampling in areas historically 303 with high numbers of human cases but has led to a paucity of sequences from elsewhere in 304 the endemic region. The limited number of full segment sequences from rodents, from few 305 306 geographic locations, limits our understanding of viral radiation in rodent hosts, particularly from species which are not considered the primary reservoir, e.g., *H. pamfi*. The most recent 307 common ancestor for the viral sequence obtained from *H. pamfi* is estimated to be in the late 308 1600s, it is therefore possible lineage VI and/or H. pamfi as a reservoir of LASV has gone 309 310 undetected due to lack of sufficient sampling (15).

311

Interpreting available LASV sequences is challenging for several reasons. A large proportion of available sequences (70%) have been obtained within Lassa fever research programs, representing spatial ascertainment bias (38–40). In addition to these spatial biases' temporal biases are apparent. Since 2016 there has been a substantial increase in the number of LASV sequences available in NCBI GenBank, reflecting increasing research effort, availability of sequencing platforms and increased data collection during Lassa fever epidemics, such as in

Page 13 of 18

318 the 2018 Nigeria Lassa fever outbreak (41-43). There are notably fewer recorded sequences 319 of LASV from Benin, Togo, and Ghana, suggesting a potential a gap in surveillance and 320 research capacity in these locations or a lack of circulating LASV, despite several reported outbreaks (44-46). Phylogenetic analysis on 60% of our initial dataset, following removal of 321 322 sequences due to incompleteness or missing geographic and year of collection information (n = 1.045) demonstrated geographic clustering of LASV lineages, supporting prior analyses 323 (14-16,33,44,47-49). Increased data availability from Nigeria following increased LASV 324 surveillance allowed regional analysis of phylogeny for lineages II and III supporting previous 325 326 findings of expansion of these lineages from North-East Nigeria to the South-West of the country (13,50,51). 327

328

A substantial number (n = 869) of the sequences retrieved corresponded to short fragments 329 (< 1 Kb) probably derived from PCR products used for diagnostic purposes rather than for 330 viral genomic surveillance. LASV is a segmented virus, and it was not possible to identify 331 complete genome sequences since both S and L segments are reported separately on the 332 sequence's repository. The molecular clock analyses from L protein indicated an earlier 333 334 emergence of LASV when compared to S segment analysis (828 and 1350 respectively), 335 potentially because the viral RNA polymerase (L protein) is less affected by selective 336 pressure than the S segment (12,47,52).

337

Despite these challenges, this study has synthesised currently available data on LASV 338 sequences to investigate the location and period of sampling to reconstruct the dispersal of 339 viral lineages across the endemic region. Despite the regionalisation of LF being driven by 340 rodent-to-human transmission, there remains scarce LASV genomic data from non-human 341 hosts. We have mapped the locations of relative under sampling to guide targeted efforts to 342 counteract biases in currently available data for both rodent and human derived sequences. 343 Expanded sampling of LASV from animal species within the endemic region will improve our 344 current understanding of LASV evolution and ecology and improve confidence in current 345 estimates of westward expansion of Lassa fever in humans. Further understanding of the 346 viral evolution dynamics of LASV and spatial expansion of current lineages will be vital to 347 348 ensure adequate diagnostic tools are available to respond to the expected sporadic 349 outbreaks of Lassa Fever across the region.

350

351 Supplementary material

Page 14 of 18

S1 Data. GenBank accession number of analysed sequences. This dataset includes
 available data about host, country, region, year, sequence length, genome segment (L or S)
 and predicted MRCA.

356

S2 Data. Dataset on confirmed Lassa fever cases. This presents the number of confirmed cases of Lassa fever reported from countries between 2008 and 2023 at a subnational level that were used to calculate the number of cases per 100,000 people. References for the reports used to produce this dataset are included.

361

S1 Figure. Map of West Africa. displays a map of West Africa with country names for
 reference with Fig 1 and Fig 2. Shapefiles for mapping obtained from GADM 4.0.2 (35)

364

S2 Figure. Time-calibrated phylogeny for both the small segment (S) and large segment (L) from included LASV sequences.

367

368 Author contributions

Conceptualisation: DS and LBA; Methodology: HF, DS, DA and LBA; Formal Analyses: HF, DS and LBA; Investigation: HF, DS and LBA; Supervision: LBA; Data Curation: HF and DS;

- Writing original draft preparation: HF, DS, LBA; Writing Review and Editing: IH, LE, NH,
- 872 RA, RK, FN, DA, AZ and TMcH; Funding acquisition: AZ and FN.
- 373

374 Data availability and reproducibility

All data used in these analyses are publicly available from GenBank. The accession numbers 375 of records used are available as supplementary material. Code to reproduce the metadata 376 analyses available archived Git release Zenodo 377 are as an on 378 (https://doi.org/10.5281/zenodo.6340162)

379

380 Conflict of interests

- 381 The authors declare no conflict of interests
- 382

383 Acknowledgements:

Linzy Elton, Timothy D McHugh, Francine Ntoumi, and Alimuddin Zumla acknowledge support from EDCTP-Central Africa and East African Clinical Research Networks (CANTAM-3, EACCR-3). Sir Zumla is an NIHR Senior Investigator, a Mahathir Science Award, Sir Patrick Manson Medal and EU-EDCTP Pascoal Mocumbi Prize laureate. Liã Bárbara Arruda, David Simons, Rashid Ansumana, Linzy Elton, Najmul Haider, Isobella Honeyborne, Danny Asogun, Timothy D McHugh, Francine Ntoumi, Alimuddin Zumla and Richard Kock acknowledge

Page 15 of 18

- 390 support from the Pan-African Network for Rapid Research, Response and Preparedness for
- 391 Infectious Diseases Epidemics PANDORA-ID-NET, funded through the European and
- 392 Developing Countries Clinical Trials Partnership (EDCTP) (grant number RIA2016E-1609).
- 393 David Simons is supported by a PhD studentship from the UK Biotechnology and Biological
- 394 Sciences Research Council (BB/M009513/1).
- 395

396 **References**

- Asogun DA, Gunther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical
 Features, Diagnosis, Management and Prevention. [Review]. Infectious Disease Clinics of North
 America. 2019;33(4):933–51.
- Basinski AJ, Fichet-Calvet E, Sjodin AR, Varrelman TJ, Remien CH, Layman NC, et al. Bridging the
 gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West
 Africa. Wesolowski A, editor. PLoS Comput Biol. 2021 Mar 3;17(3):e1008811.
- World Health Organisation. Lassa fever [Internet]. 2022 [cited 2022 Feb 22]. Available from:
 https://www.who.int/health-topics/lassa-fever#tab=tab_1
- Gunther S, Lenz O. Lassa virus. [Review] [323 refs]. Critical Reviews in Clinical Laboratory
 Sciences. 2004;41(4):339–90.
- 407 5. Hallam SJ, Koma T, Maruyama J, Paessler S. Review of Mammarenavirus Biology and Replication.
 408 Front Microbiol [Internet]. 2018 [cited 2020 Oct 21];9. Available from:
 409 https://www.frontiersin.org/articles/10.3389/fmicb.2018.01751/full
- Welch SR, Scholte FEM, Albariño CG, Kainulainen MH, Coleman-McCray JD, Guerrero LW, et al.
 The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus
 Reassortants in a Guinea Pig Model. Frontiers in Cellular and Infection Microbiology [Internet].
 2018 [cited 2022 Feb 3];8. Available from:
- 414 https://www.frontiersin.org/article/10.3389/fcimb.2018.00240
- 415 7. Simons D. Lassa fever cases suffer from severe underreporting based on reported fatalities.
 416 International Health. 2022;
- 417 8. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the
 418 epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155(3):437–44.
- 419 9. Takah NF, Brangel P, Shrestha P, Peeling R. Sensitivity and specificity of diagnostic tests for Lassa
 420 fever: a systematic review. BMC Infectious Diseases. 2019 Jul 19;19(1):647.
- 10. Nnaji ND, Onyeaka H, Reuben RC, Uwishema O, Olovo CV, Anyogu A. The deuce-ace of Lassa
 Fever, Ebola virus disease and COVID-19 simultaneous infections and epidemics in West Africa:
 clinical and public health implications. Tropical Medicine and Health. 2021 Dec 30;49(1):102.
- 424 11. Ashcroft JW, Olayinka A, Ndodo N, Lewandowski K, Curran MD, Nwafor CD, et al. Pathogens that
 425 Cause Illness Clinically Indistinguishable from Lassa Fever, Nigeria, 2018. Emerging Infectious
 426 Diseases. 2022;28(5):994–7.
- 427 12. Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE, Moses LM, et al. Clinical Sequencing
 428 Uncovers Origins and Evolution of Lassa Virus. Cell. 2015;

Page 16 of 18

- 429 13. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, et al. Genetic Diversity
 430 among Lassa Virus Strains. Journal of Virology. 2000;74(15):6992–7004.
- 431 14. Manning JT, Forrester N, Paessler S. Lassa virus isolates from Mali and the Ivory Coast represent
 432 an emerging fifth lineage. Frontiers in Microbiology. 2015;
- 433 15. Olayemi A, Cadar D, Magassouba N, Obadare A, Kourouma F, Oyeyiola A, et al. New Hosts of The
 434 Lassa Virus. Scientific Reports. 2016;
- 435 16. Olayemi A, Adesina AS, Strecker T, Magassouba N, Fichet-Calvet E. Determining ancestry
 436 between rodent-and human-derived virus sequences in endemic foci: Towards a more integral
 437 molecular epidemiology of lassa fever within West Africa. Biology. 2020;
- 438 17. Whitmer SLM, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, et al. New lineage of lassa virus,
 439 Togo, 2016. Emerging Infectious Diseases. 2018;24(3):599–602.
- 440 18. Okoro OA, Bamgboye E, Dan-Nwafor C, Umeokonkwo C, Ilori E, Yashe R, et al. Descriptive
 441 epidemiology of Lassa fever in Nigeria, 2012-2017. Pan Afr Med J. 2020 Sep 3;37:15.
- Klitting R, Kafetzopoulou LE, Thiery W, Dudas G, Gryseels S, Kotamarthi A, et al. Predicting the
 evolution of Lassa Virus endemic area and population at risk over the next decades [Internet].
 Microbiology; 2021 Sep [cited 2022 Feb 3]. Available from:
 http://biorxiv.org/lookup/doi/10.1101/2021.09.22.461380
- 20. Bangura U, Buanie J, Lamin J, Davis C, Bongo GN, Dawson M, et al. Lassa Virus Circulation in
 Small Mammal Populations in Bo District, Sierra Leone [Internet]. Vol. 10, BIOLOGY-BASEL. ST
 ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND: MDPI; 2021. Available from:
 https://doi.org/10.3390/biology10010028
- 450 21. Forni D, Sironi M. Population Structure of Lassa Mammarenavirus in West Africa. Viruses.
 451 2020;12(4):437.
- 452 22. Lecompte E, Fichet-Calvet E, Daffis S, Koulémou K, Sylla O, Kourouma F, et al. Mastomys
 453 natalensis and Lassa fever, West Africa. Emerging Infectious Diseases. 2006;
- 454 23. Wulff H, Fabiyi A, Monath TP. Recent isolations of Lassa virus from Nigerian rodents. Bull World
 455 Health Organ. 1975;52(4–6):609–13.
- 456 24. Yadouleton A, Agolinou A, Kourouma F, Saizonou R, Pahlmann M, Bedié SK, et al. Lassa virus in
 457 pygmy mice, Benin, 2016-2017. Emerging Infectious Diseases. 2019;
- 458 25. Oti VB. A Reemerging Lassa Virus: Aspects of Its Structure, Replication, Pathogenicity and
 459 Diagnosis. In: Alfonso J. Rodriguez-Morales, editor. Current Topics in Tropical Emerging Diseases
 460 and Travel Medicine. BoD Books on Demand; 2018.
- 461 26. Lo Iacono G, Cunningham AA, Fichet-Calvet E, Garry RF, Grant DS, Khan SH, et al. Using
 462 Modelling to Disentangle the Relative Contributions of Zoonotic and Anthroponotic
 463 Transmission: The Case of Lassa Fever. PLoS Neglected Tropical Diseases. 2015;
- 464 27. National Center for Biotechnology Information. National Center for Biotechnology Information
 465 [Internet]. 2022 [cited 2022 Feb 3]. Available from: https://www.ncbi.nlm.nih.gov/
- 466 28. Becker G, Lawrence M. genbankr: Parsing GenBank files into semantically useful objects. 2021.

Page 17 of 18

- 467 29. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna,
 468 Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R469 project.org/
- 470 30. Kahle D, Wickham H. ggmap: Spatial Visualization with ggplot2. The R Journal. 2013;5(1):144–61.
- 471 31. Wood SN. Generalized Additive Models: An Introduction with R. 2nd ed. Chapman and Hall/CRC;
 472 2017.
- 473 32. Suchard MA, Lemey P, Baele G, Ayres DL, Drummond AJ, Rambaut A. Bayesian phylogenetic and
 474 phylodynamic data integration using BEAST 1.10. Virus Evolution. 2018;
- 475 33. Olayemi A, Fichet-Calvet E. Systematics, ecology, and host switching: Attributes affecting
 476 emergence of the Lassa virus in rodents across western Africa. Viruses. 2020.
- 477 34. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in Bayesian
 478 phylogenetics using Tracer 1.7. Systematic Biology. 2018;
- 479 35. Database of Global Administrative Areas. GADM [Internet]. 2022 [cited 2021 Apr 25]. Available
 480 from: https://gadm.org/index.html
- 481 36. Whitlock AOB, Bird BH, Ghersi B, Davison AJ, Hughes J, Nichols J, et al. Identifying the genetic
 482 basis of viral spillover using Lassa virus as a test case. R Soc Open Sci. 2023 Mar 22;10(3):221503.
- 483 37. Lecompte E, Brouat C, Duplantier JM, Galan M, Granjon L, Loiseau A, et al. Molecular
 484 identification of four cryptic species of Mastomys (Rodentia, Murinae). Biochemical Systematics
 485 and Ecology. 2005;
- 38. Townsend Peterson A, Moses LM, Bausch DG. Mapping transmission risk of lassa fever in West
 Africa: The importance of quality control, sampling bias, and error weighting. PLoS ONE. 2014;
- 488 39. Ehichioya DU, Hass M, Ölschläger S, Becker-Ziaja B, Onyebuchi Chukwu CO, Coker J, et al. Lassa
 489 fever, Nigeria, 2005-2008. Emerging Infectious Diseases. 2010.
- 40. Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A, et al. New opportunities for field research
 491 on the pathogenesis and treatment of Lassa fever. Antiviral Research. 2008;
- 41. Maxmen A. Deadly Lassa-fever outbreak tests Nigeria's revamped health agency. Nature.
 2018;555(7697):421-2.
- 494 42. Siddle KJ, Eromon P, Barnes KG, Mehta S, Oguzie JU, Odia I, et al. Genomic Analysis of Lassa
 495 Virus during an Increase in Cases in Nigeria in 2018. New England Journal of Medicine. 2018 Nov
 496 1;379(18):1745–53.
- 43. Ilori EA, Frank C, Dan-Nwafor CC, Ipadeola O, Krings A, Ukponu W, et al. Increase in Lassa Fever
 498 Cases in Nigeria, January–March 2018. Emerging Infectious Diseases [Internet]. 2019 May [cited
 499 2020 Oct 21];25(5). Available from: 10.3201/eid2505.181247
- 44. Yadouleton A, Picard C, Rieger T, Loko F, Cadar D, Kouthon EC, et al. Lassa fever in Benin:
 description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus.
 Emerging Microbes & Infections. 2020;1–23.

Page 18 of 18

- 45. World Health Organisation. Lassa Fever Togo [Internet]. 2022 [cited 2022 Nov 24]. Available
 from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON362
- 46. Ghana Health Services. Lassa Fever Press Release Ghana 2023. 2023 Apr 19 [cited 2023 Apr 19];
 Available from: https://osf.io/ft2gy/
- 47. Ibukun FI. Inter-lineage variation of lassa virus glycoprotein epitopes: A challenge to lassa virus
 vaccine development. Viruses. 2020.
- 48. Lalis A, Leblois R, Lecompte E, Denys C, ter Meulen J, Wirth T. The Impact of Human Conflict on
 the Genetics of Mastomys natalensis and Lassa Virus in West Africa. PLoS ONE. 2013;7(5).
- 49. Wiley MR, Fakoli L, Letizia AG, Welch SR, Ladner JT, Prieto K, et al. Lassa virus circulating in
 Liberia: a retrospective genomic characterisation. The Lancet Infectious Diseases. 2019;
- 50. Ehichioya DU, Hass M, Becker-Ziaja B, Ehimuan J, Asogun DA, Fichet-Calvet E, et al. Current molecular epidemiology of Lassa virus in Nigeria. Journal of Clinical Microbiology. 2011;
- 51. Naidoo D, Ihekweazu C. Nigeria's efforts to strengthen laboratory diagnostics Why access to
 reliable and affordable diagnostics is key to building resilient laboratory systems. African Journal
 of Laboratory Medicine [Internet]. 2020 Aug 26 [cited 2020 Oct 21];9(2). Available from:
 10.4102/ajlm.v9i2.1019
- 519 52. Hastie KM, Saphire EO. Lassa virus glycoprotein: stopping a moving target. Current Opinion in 520 Virology. 2018.



Human

25°N



